Suggested remit - To appraise the clinical and cost effectiveness of anakinra within its marketing authorisation for treating Still's disease
 
Status In progress
Process STA 2018
ID number 1463

Project Team

Project lead James Maskrey

Email enquiries

Consultees

Companies sponsors Swedish Orphan Biovitrum (anakinra)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Professional groups Royal College of Physicians

Commentators

Comparator companies Accord Healthcare (mycophenolate, methotrexate) (not signed confidentiality agreement)
  Baxter Healthcare (cyclophosphamide) (not signed confidentiality agreement)
  Bristol Laboratories (hydroxychloroquine) (not signed confidentiality agreement)
  Concordia International (methotrexate) (not signed confidentiality agreement)
  Creo Pharma (hydroxychloroquine) (not signed confidentiality agreement)
  Genesis Pharmaceuticals (sulfasalazine) (not signed confidentiality agreement)
  Hospira UK (methotrexate) (not signed confidentiality agreement)
  Medac UK (leflunomide, methotrexate) (not signed confidentiality agreement)
  Mylan (ciclosporin, leflunomide) (not signed confidentiality agreement)
  Nordic Pharma (methotrexate) (not signed confidentiality agreement)
  Novartis (ciclosporin, mycophenolate, canakinumab) (not signed confidentiality agreement)
  Orion Pharma (methotrexate) (not signed confidentiality agreement)
  Pfizer (sulfasalazine, methotrexate) (not signed confidentiality agreement)
  Roche (tocilizumab, mycophenolate) (not signed confidentiality agreement)
  Rosemont Pharmaceuticals (sulfasalazine, methotrexate) (not signed confidentiality agreement)
  Sandoz (cyclophosphamide, methotrexate) (not signed confidentiality agreement)
  Sanofi (leflunomide) (not signed confidentiality agreement)
  Teva UK (ciclosporin, mycophenolate, methotrexate, hydroxychloroquine) (not signed confidentiality agreement)
  Therakind (methotrexate) (not signed confidentiality agreement)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee

Timeline

Key events during the development of the guidance:

Date Update
07 March 2019 Invitation to participate
07 March 2019 In progress, Appraisal start
26 September 2018 - 24 October 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance